Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

AML1/ETO (RUNX1/RUNX1T1) Translocation, Dual Fusion FISH Probe Kit

FusionPlex™ Pan-Heme panel

AML1/ETO (RUNX1/RUNX1T1) Translocation, Dual Fusion FISH Probe Kit

FusionPlex™ Pan-Heme panel

›

RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2
RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	DA Sensitive: C3 – Early Trials DA Sensitive : C3	DA Sensitive: C3 – Early Trials DA Sensitive : C3
RUNX1-RUNX1T1 fusion + KIT D816	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion + KIT D816	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	DAV Sensitive: C3 – Early Trials DAV Sensitive : C3	DAV Sensitive: C3 – Early Trials DAV Sensitive : C3
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	CLAG Resistant: C4 – Case Studies CLAG Resistant : C4	CLAG Resistant: C4 – Case Studies CLAG Resistant : C4
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C4 – Case Studies venetoclax + midostaurin Sensitive : C4	venetoclax + midostaurin Sensitive: C4 – Case Studies venetoclax + midostaurin Sensitive : C4
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	IA Resistant: C4 – Case Studies IA Resistant : C4	IA Resistant: C4 – Case Studies IA Resistant : C4
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C4 – Case Studies venetoclax Resistant : C4	venetoclax Resistant: C4 – Case Studies venetoclax Resistant : C4
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Sensitive: C4 – Case Studies venetoclax + midostaurin Sensitive : C4	venetoclax + midostaurin Sensitive: C4 – Case Studies venetoclax + midostaurin Sensitive : C4
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C4 – Case Studies venetoclax Resistant : C4	venetoclax Resistant: C4 – Case Studies venetoclax Resistant : C4
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation	Acute Myelogenous Leukemia	Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation	Acute Myelogenous Leukemia	IA Resistant: C4 – Case Studies IA Resistant : C4	IA Resistant: C4 – Case Studies IA Resistant : C4